facebook
twitter
instagram
linkedin
pinterest
youtube
magnify
user
heart
arrow-right
chevron-up
chevron-left
chevron-right
chevron-down
Javascript must be enabled for the correct page display
Skip to Content
User icon
NEALS Member Portal
Search Trials
Contact a Specialist
Community Education Webinars
Heart icon
Donate
Search icon
Search
Search icon
Search
People Living with ALS
About ALS and Motor Neuron Disease
Community Education Webinars
ALS Clinical Research Learning Institute®
Online ALS Resources
Additional Resources & Information
Get Involved
ALS Researchers
Become a NEALS Member
NEALS Clinical Trial Capabilities
2025 Annual NEALS Meeting
NEALS Single Institutional Review Board (cIRB)
NEALS Sample Repository
Historical Trial Data
Post an ALS Clinical Trial
Upcoming Research Opportunities
Collaborate with NEALS
NEALS Scientific Advisory Board
NEALS Affiliated Trials
PEACe Committee
ALS Research & Trials
ALS Clinical Research
Search for a Trial
Expanded Access
Trial News & Events
About
Our Mission
Our Structure
NEALS Member Sites
Contact Us
Join Our Email List
Search Trials
Contact a Specialist
Community Education Webinars
Search form
Search:
Search icon
Search close
HOME
SEARCH RESULTS
Search Results
Your search for “
” returned 943 result(s)
Homepage →
People Living with ALS →
About ALS and Motor Neuron Disease →
ALS Researchers →
Collaborate with NEALS | NEALS SAB →
ALS Trials →
About →
Become a NEALS Member →
ALS Clinical Research →
Our Mission →
Our Structure →
NEALS Clinical Trial Capabilities →
Jonathan Glass, MD →
ALS Clinical Research Learning Institute® →
Online ALS Resources →
Get Involved →
Donate Samples →
Additional Resources & Information →
NEALS Sample Repository →
NEALS sample inventory →
Historical Trial Data →
Post an ALS Clinical Trial →
Upcoming Research Opportunities →
What are clinical trials and why are they important? →
Getting involved in a Clinical Trial →
Understanding Placebo-Controlled Trials →
Clinical Trial Definitions →
How to Navigate Clinicaltrials.gov →
Expanded Access →
Contact Us →
Make an Impact →
NEALS →
Hilda Gonzalez Gonzalez →
Stephen Winthrop →
Marilyn Sanford →
Ron Busch →
Cari Meystrik →
Doug Clough →
Mary Luper →
Randy Floyd →
Allison Pogemiller →
Bryan Stone →
Jim Woodman →
Kim Abbott →
Jerry Creehan →
Jeff Arison →
Sonia Usatch-Kuhn →
Deb Paust →
Pattie Hamlin →
Donna Behler McArthur →
Amber Montanez →
Dawn Rowe-Morling →
Loretta Frawley →
Dawn Boushelle →
Ellen Mooney →
Joe Mooney →
Abby Chirico →
M Jane Williamson →
Ed Clark →
Justin Clark →
Mike Leist →
Lauren Saah →
Lorri Carey →
Patrick Revere →
Herman Green →
David & Jill Brattain →
Scmf →
Jackie Zamojski →
Carly Allen Test →
Stacey Crowder →
Joseph Manginelli →
Gwen Petersen →
Christine Moretti →
Mollie Elkman →
Melissa Popp →
Sunny Brous →
Bonnie Harris →
Mark Buermann →
Gregg Kochakji →
Ken Menkhaus →
James F. Thiessen →
Diana Thiessen →
Lisa Deegan →
Michael Lose →
Mary McDonald →
Bruce Rosenblum →
Juan A Reyes →
Linda Tolisano →
Matt & Karen Toole →
sarah ehrlich →
David Doane →
Karen Steffens →
Robert Faulstich →
Jean Swidler →
Todd Kelly →
Todd Kelly →
Michaela Murphy →
Jennifer Barrett Fajardo →
Jeffrey Hurley →
Sandra Mikush →
Opportunities and Tips for Raising ALS Awareness & Advocacy →
ALS Clinical Trial Pipeline Series - Fall 2016 →
C9: From ID (Identification) to Therapy →
Ibudilast trials in ALS →
ALS Clinical Trial Pipeline Series - Spring 2016 →
Clinical Trial of Ezogabine (Retigabine) on Motor Neuron Excitability in ALS →
Answer ALS →
Novel Tools to Accelerate the Pace of ALS Clinical Drug Development →
ALSUntangled - Re-Opening the X-Files →
Updates in Nutritional Interventions for ALS →
A Phase II Study in ALS of the Effects of Mexiletine on Hyperexcitability of Motor Neurons →
Research Updates - NEALS & MNDA →
ALS and the Clinical Trial Process →
ALS Clinical Trial Pipeline Series - Fall 2015 →
Compassion Fatigue in ALS →
A "Cool" New Duke ALS Research Program Focused on ALS Reversals →
Assistive Technology Options for Individuals with ALS →
ALS Clinical Trial Pipeline Series - Spring 2015 →
Why do people get ALS? Epidemiological studies to find answers →
Scientific Updates on ALS; NEALS & AAN →
Clinical Trial of Ezogabine (Retigabine) on Motor Neuron Excitability in ALS →
Clinical Trial Design and the Evaluation of Small Trials →
Clinical Trial Pipeline Series-Winter 2015 →
Diaphragm Pacing System →
Expanded Access →
ALSA/NEALS PALS Webinar: 'Right to Try' Discussion →
ALSA/NEALS PALS Webinar: Mexiletine Study Results Overview →
ALSA/NEALS PALS Webinar: Clinical Trial Pipeline Series - Summer 2014 →
Diaphragm Pacing System™ (DPS) In Participants with Amyotrophic Lateral Sclerosis: An Informational →
ALSA/NEALS PALS Webinar: Stem Cells →
ALSA/NEALS PALS Webinar: Tele-medicine →
ALSA/NEALS PALS Webinar: Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis →
ALSA/NEALS PALS Webinar: Biomarkers in ALS →
ALSA/NEALS PALS Webinar: ALS Clinical Trial Pipeline Series - Winter 2014 →
Diaphragm Pacing System (DPS) in Participants with ALS - Clinical Trial: An Informational NEALS Webi →
ALSUntangled: Opening the X-Files of ALS 7-31-13 →
TDI-132/Gilenya Informational Webinar 6-26-13 →
Genetic Research in ALS 6-18-13 →
Selection Trial of High Dosage Creatine & Two Dosages of Tamoxifen Webinar 5-20-13 →
Spring 2013 ALS Clinical Trial Pipeline Series 3-27-13 →
BENEFIT-ALS: Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv →
Mexiletine for Patients with Sporadic ALS 1-11-13 →
ALS Clinical Trials: Expediting Therapy Development 11-30-12 →
Resistance and Endurance Exercise in ALS Trial Webinar 9-11-12 →
Upper Motor Neuron Disease Research Webinar 7-2-12 →
Determining the Effect of Nuedexta on Speech and Swallowing in ALS: A Multicenter Trial Webinar →
Informed Consent and Ethical Considerations in Research Webinar 4-30-12 →
Imaging Biomarkers Research Webinar 4-16-12 →
Clinical Trial Design Webinar 3-20-12 →
Stem Cell Webinar 3-13-12 →
Supporting Advocacy Efforts Webinar 2-13-12 →
Maximizing Bulbar and Respiratory Function in Amyotrophic Lateral Sclerosis: Updates in Best Managem →
Cannabinoid use in ALS: Only symptom management or more? →
A User's Guide to Genetic Testing in ALS →
Actemra Study - Anti-inflammatory treatment for ALS →
Neuraltus NP001 Phase 2 Trial: Targeting Neuroinflammation to Slow ALS Progression →
ALS Clinical Trial Pipeline Series - Spring 2017 →
Clinical Trial of Ezogabine (Retigabine) on Motor Neuron Excitability in ALS →
ALS Research Counts on You - Learn How the National ALS Registry Advances Research →
Results from the Immunosuppression in ALS Trial →
A Phase II Study in ALS of the Effects of Mexiletine on Hyperexcitability of Motor Neurons →
Exercise and ALS: A Discussion of Research and Practical Recommendations →
Power Wheelchair: Documentation Requirements →
Retigabine Clinical Trial Update & Discussion with ALS Patient and Advocate Stephen Winthrop →
Advanced Imaging Tools for Accelerating Drug Development in ALS →
Power Wheelchairs - The Basics and Beyond →
ALS AT HOME: Bringing research home to you →
Environmental Risk Factors for Amyotrophic Lateral Sclerosis →
Lazarus by Lunasin? Untangling an ALS X-File →
ALSA-BIO3: Building future success through biomarkers →
The Centaur trial: a phase 2 trial of AMX0035 for the treatment of ALS →
Actemra Clinical Trial Update →
Fortitude ALS: A Phase 2 study of CK107 to treat respiratory and motor function in ALS →
Radicava: A Review of Clinical Trial Data and Drug Considerations →
ALS Clinical Trial Pipeline Series - Spring 2018 →
A Randomized Controlled Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis →
The Centaur trial: a phase 2 trial of AMX0035 for the treatment of ALS →
Proactive and Collaborative Consideration of Augmentative Communication Tools and Strategies →
Nutrition in ALS: How to EAT MORE! →
Treating Respiratory Dysfunction in ALS →
Cured by Curcumin? Untangling another ALS X-file →
The Centaur trial: a phase 2 trial of AMX0035 for the treatment of ALS →
Right to Try? Historical, Legal and Ethical Considerations →
The Merging of Science and Technology in ALS Research →
The VA and ALS: An overview for veterans with ALS and clinicians. →
Update on Stem Cell Trials in ALS: NurOwn and Other Studies →
The Trach Decision from an ALS Patient's Perspective →
The REFALS Trial: A Phase 3 Trial of Oral Levosimendan on Respiratory Function in PALS →
BrainGate: Toward Restoring Communication and Mobility for People with ALS →
Accelerating Therapy Development and Expanding Access →
Postcards from the Edge: Updates on Six Unusual ALS Projects. →
The Neuropathology of ALS: What can we learn? →
ALS Clinical Trial Pipeline Series - Winter 2019 →
Palliative Care in ALS Clinic →
Gene-targeted Therapeutics for ALS →
REFINE-ALS: A Much Needed Biomarker Study of Edaravone (Radicava) in ALS →
I Just Took a DNA test - Turns Out I Don't Have All the Answers →
ROADS to a better ALS outcome measure: the new Rasch-Built Overall ALS Disability Scale (ROADS). →
Simplifying the Search: How to Find the Right ALS Clinical Trial for You →
ALS Clinical Research Learning Institutes: Empowering People with ALS to be Research Ambassadors →
Results of the CENTAUR study: a trial of AMX0035 for people with ALS →
I AM ALS presents ALS Signal and PaCTD: Patient Centric Tools →
ALS Nutrition App - Cooking Demonstrations and Ask a Dietitian Session! →
AMX0035 Results: Implications for People with ALS →
Is the Key to Stopping ALS Being Flushed Down Our Toilets? →
Results of the REFALS Study →
Long-Term Survival of Participants in the CENTAUR Trial →
Open Label Extension Study Results of AMX0035: Implications for People with ALS →
BrainGate: Brain-Computer Interfaces Toward the Maintenance and Restoration of Communication & Mobil →
Expanded Access to Investigational Drugs →
ALS Drug Development Webinar Series Part 1: Scientific Considerations →
ALS Drug Development Webinar Series Part 2: Regulatory Considerations →
REFINE-ALS: Finding Biomarkers of Edaravone (Radicava) Effect - From the Comfort of Your Home →
Maximizing Repositories to Accelerate ALS Research: Biofluids, Tissues, Cells and Data →
ALS Drug Development Webinar Series Part 3: Ethical Considerations →
ALS Drug Development Webinar Series Part 4: Site Considerations →
An Update on the CENTAUR Trial: a Trial of AMX0035 in ALS →
ALS Clinical Trial Pipeline Webinar →
Moving research forward using Answer ALS resources →
Brain-Computer Interfaces for Communication Impairments →
ALS Drug Development Webinar Series Part 6: Research Engagement by People Living With ALS →
ALS Drug Development Webinar Series Part 5: Preclinical Development of Potential Therapies →
An Update on AMX0035 and Design of the Phase 3 PHOENIX Study →
Courage ALS, a Phase 3 Trial of Reldesemtiv in ALS →
Phase 2a trial of Oral LAM-002A capsules in C9ORF72 ALS →
The ATLAS Study: A Clinical Trial for Adults with a Confirmed Superoxide Dismutase 1 (SOD1) Mutation without Signs or Symptoms of Amyotrophic Lateral Sclerosis (ALS) →
The Latest on Expanded Access Protocols in ALS →
How Professionals Can Help the Kids in ALS Families →
Emergency Preparedness Considerations for People with ALS and Their Caregivers →
Research and Support for Young Caregivers and Families Affected by ALS →
Impact of COVID-19 on ALS clinical research →
Update #2: Impact of COVID-19 on ALS clinical research →
ALS - Biosample Collection Efforts to Accelerate Research: Biofluids, Tissues, Cells and Data →
Suppressing Neuroinflammation in Neurodegenerative Diseases →
2025 Annual NEALS Meeting →
2018 NEALS Annual Meeting Photo Gallery →
Gale Kittle, RN, MPH →
Sabrina Paganoni, MD, PhD →
Matthew Harms, MD →
Richard Bedlack, MD, PhD →
Robert Bowser, PhD →
Nicholas Maragakis, MD →
Clotilde Lagier-Tourenne MD, PhD →
Jinsy Andrews, MD, MSc →
Jeremy Shefner, MD, PhD →
Timothy Miller, MD, PhD →
Robert Brown, Jr. MD, DPhil →
James Berry, MD, MPH →
Merit Cudkowicz MD, MSc →
Jeffrey Rothstein MD, PhD →
NEALS Data Sharing Policy →
Beverly Smits, MBA →
NEALS Single Institutional Review Board (cIRB) →
Join Our Email List →
A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD →
Pathogenesis in C9Orf72-Related ALS (Picals) →
Longitudinal Assessment of the Gut Microbiome in People with ALS →
NEALS Committees →
Abstract Submission →
"Mitsubishi Tanabe Pharma America Announces FDA Approval of RADICAVA ORS® (edaravone) for the Treatment of ALS," published by Mitsubishi Tanabe Pharma America →
"The HEALEY ALS Platform Trial announces first participants enrolled for investigational product SLS-005 (Trehalose)," published by the Sean M. Healey & AMG Center for ALS →
Healey ALS Platform Trial Regimen E: A Participant’s Guide →
"Coya Therapeutics Announces Annals of Neurology Publication Featuring Biomarker Data in ALS Patients Treated with Tregs Cell Therapy," published by Coya Therapeutics →
"AI Therapeutics Announces Initiation of a Phase II Clinical Trial of AIT-101 for Treatment of ALS," published by AI Therapeutics →
"New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS," published by Biogen →
Carly Allen →
NCT05357950 →
NCT04948645 →
NCT05183152 →
NCT05237284 →
NCT05279755 →
NCT05306457 →
NCT05218668 →
NCT05163886 →
NCT05104710 →
NCT05116943 →
NCT05176093 →
NCT03851302 →
NCT05137665 →
NCT05006352 →
NCT05021536 →
NCT04993755 →
NCT04987671 →
NCT05039099 →
NCT04944784 →
NCT05067179 →
NCT04866771 →
NCT04749433 →
NCT04856982 →
NCT04569435 →
NCT04768972 →
NCT04715399 →
NCT04569084 →
NCT04559009 →
NCT04494256 →
NCT04575727 →
NCT04490148 →
NCT04057898 →
NCT04394871 →
NCT01900132 →
NCT04363684 →
NCT04150809 →
NCT04297683-NEALS →
NCT04097158 →
NCT04066244 →
NCT04220190 →
NCT04220021 →
NCT04259255 →
NCT04026581 →
NCT03865420 →
NCT03690791 →
NCT00004568 →
NCT00136500 →
NCT00317616 →
NCT00801333 →
NCT00821132 →
NCT00912041 →
NCT01772602 →
NCT02118805 →
NCT02360891 →
NCT02437110 →
NCT02869048 →
NCT02962050 →
NCT03020797 →
NCT03088839 →
NCT03100110 →
NCT03127267 →
NCT03217396 →
NCT03225144 →
NCT03268603 →
NCT03293069 →
NCT03362658 →
NCT03366506 →
NCT03367650 →
NCT03452618 →
NCT03567213 →
NCT03578796 →
NCT03579017 →
NCT03580616 →
NCT03645031 →
NCT03651349 →
NCT03652805 →
NCT03755167 →
NCT03766321 →
NCT03800524 →
NCT03827187 →
NCT03835507 →
NCT03944447 →
NCT03984708 →
NCT04008329 →
NCT04244630 →
NCT04257760 →
NCT04293484 →
NCT04302870 →
NCT04326283 →
NCT04328675 →
NCT04393467 →
NCT04406675 →
NCT04454892 →
NCT04518540 →
NCT04562831 →
NCT04654689 →
NCT04686110 →
NCT04691011 →
NCT04719403 →
NCT04744532 →
NCT04745299 →
NCT04762589 →
NCT04788745 →
NCT04797845 →
NCT04798183 →
NCT04809675 →
NCT04816227 →
NCT04819555 →
NCT04858555 →
NCT04868994 →
NCT04882904 →
NCT04885374 →
NCT04889898 →
NCT04918251 →
NCT04931862 →
NCT04939818 →
NCT04950647 →
NCT04950933 →
NCT04952038 →
NCT04952155 →
NCT04953286 →
NCT04953481 →
NCT04953624 →
NCT04956822 →
NCT05003921 →
NCT05031351 →
NCT05039268 →
NCT05095571 →
NCT05151471 →
NCT05178810 →
NCT05193994 →
NCT05276349 →
NCT05309408 →
NCT05328492 →
NCT05340660 →
NCT05354622 →
NCT05407428 →
"Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS," published by Amylyx Pharmaceuticals →
NEALS5832 →
NEALS5827 →
NEALS5826 →
NCT05202743 →
NEALS5814 →
NCT05053035 →
NCT05003167 →
NEALS5788 →
NEALS5787 →
NEALS5784 →
NCT03698149 →
NCT04875416 →
NEALS5772 →
NEALS5765 →
NEALS5759 →
NCT04576650 →
NCT04505358 →
NCT04577404 →
NCT04632225 →
NCT04557410 →
NCT04579666 →
NCT04428775 →
NCT04499963 →
NCT04468919 →
NCT04468191 →
NCT04322149 →
NCT04288856 →
NCT04248465 →
NCT04245709 →
NCT04098406 →
NCT04165824 →
NCT04082832 →
NCT02870634 →
NCT03272503 →
NCT04090684 →
NCT03948178 →
NCT03836716 →
NCT04055623 →
NCT04051333 →
NCT03757351 →
NCT03986671 →
NCT03912987 →
NCT03868345 →
NCT03883581 →
NCT03843710 →
NCT03373981 →
NCT03705390 →
NCT03945279 →
NEALS5595 →
NEALS5594 →
NEALS5593 →
NEALS5592 →
NEALS5591 →
NCT02623699 →
NCT03793868 →
NCT03537807 →
NCT03707795 →
NCT03626012 →
NCT03505021 →
NCT03506425 →
NCT03214224 →
NCT03613038 →
NCT03472950 →
NCT03520517 →
NCT03411863 →
NCT03334786 →
NCT03491462 →
NCT03488524 →
NCT03489278 →
NEALS1330 →
NCT03482050 →
NCT03457753 →
NCT03456882 →
NCT02868567 →
NCT02014246 →
NCT03070119 →
NCT03338114 →
NCT03449212 →
NEALS1335 →
NCT03280056 →
NEALS1331 →
NCT02916966 →
NCT03095989 →
NCT03160898 →
NCT03068754 →
NCT03192358 →
NCT03202017 →
NCT03201991 →
NCT03196375 →
NCT03168711 →
NCT02851914 →
NCT03136809 →
NCT03127514 →
NCT03090932 →
NCT03016897 →
NCT03049046 →
NCT02936635 →
NCT02988297 →
NEALS1130 →
NCT02675075 →
NCT02872142 →
NCT02710110 →
NCT02943850 →
NEALS1221 →
NCT02759913 →
NCT02794857 →
NCT02781454 →
NCT02795897 →
NCT02819765 →
NCT02710162 →
NCT02750982 →
NCT02709330 →
NCT02714036 →
NCT02682030 →
NCT02686268 →
NCT01995903 →
NCT01954875 →
NCT01592552 →
NCT01786603 →
NCT00877604 →
NCT02017912 →
NCT00444613 →
NCT02288091 →
NCT02039401 →
NCT02011204 →
NCT01776970 →
NCT01492686 →
NCT01906658 →
NEALS1151 →
NEALS1146 →
NCT01811355 →
NCT01854294 →
NCT01849770 →
NCT01803386 →
NCT01785550 →
NCT01786174 →
NCT01806857 →
NCT02611674 →
NCT02655614 →
NEALS1206 →
NEALS1205 →
NCT02574390 →
NCT02525471 →
NCT02493491 →
NCT02457715 →
NCT02228915 →
NCT01508962 →
NCT02104921 →
NCT02374606 →
NCT02469675 →
NCT01950910 →
NCT02236897 →
NCT02414230 →
NCT02000713 →
NCT01948102 →
NCT02327845 →
NCT02365922 →
NCT02118727 →
NCT00445172 →
NCT00125203 →
NCT02290886 →
NCT02478450 →
NCT02463825 →
NCT02059759 →
NCT00107770 →
NCT02559869 →
NCT02496767 →
NCT02460679 →
NCT02469896 →
NCT02418546 →
NCT02450552 →
NCT02238626 →
NCT01835782 →
NCT01994109 →
NCT02588677 →
NCT01938495 →
NCT01879241 →
NCT02567136 →
NCT01925196 →
NCT01884571 →
NCT01730716 →
NCT01753076 →
NCT01746381 →
NCT01640067 →
NEALS1133 →
NCT01605006 →
NCT01777646 →
NEALS1126 →
NCT01592084 →
NEALS1123 →
NCT01565395 →
NCT01536249 →
NCT00015444 →
NCT01511029 →
NCT01583205 →
NCT01449578 →
NCT01486849 →
NCT01035476 →
NCT00023075 →
NCT00362362 →
NCT01143428 →
NCT01051882 →
NCT01160367 →
NCT01259050 →
NCT01123148 →
NCT01366027 →
NCT01123200 →
NCT01154283 →
NCT00718497 →
NCT01083667 →
NCT00244244 →
NCT00818389 →
NCT01089010 →
NCT00606918 →
NCT01016522 →
NCT00875446 →
NCT00956488 →
NCT00718016 →
NCT00718107 →
NCT01232738 →
NCT01281631 →
NCT01142856 →
NCT00956501 →
NCT00919555 →
NCT00620698 →
NCT00714220 →
NCT00334516 →
NCT00580593 →
NCT00537446 →
NCT00748501 →
NCT01363882 →
NCT00718003 →
NCT01082653 →
NCT01378676 →
NCT01041222 →
NCT00931944 →
NCT00677768 →
NCT01257581 →
NCT01709149 →
NEALS1131 →
NCT01699451 →
NCT01609283 →
NCT01521728 →
NCT00585572 →
NCT01495390 →
NCT01459302 →
NCT00786032 →
NCT00718458 →
NCT00716131 →
NCT00714805 →
NCT01281189 →
NCT00706147 →
NCT00983983 →
NCT01348451 →
NCT00349622 →
Genes in ALS →
"Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS," published by Amylyx Pharmaceuticals →
"Investigational drug ABBV-CLS-7262 initiates design phase for entry into the HEALEY ALS Platform Trial," published by the Sean M. Healey & AMG Center for ALS →
"FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS," published by Biogen →
Nicole Turcotte, MPH →
Update on Healey ALS Platform Trial Regimen E: Trehalose for ALS →
"FDA Advisory Committee Votes to Recommend AMX0035 for Treatment of ALS," published by NeurologyLive →
"The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS," published by Biogen →
"Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS," published by Amylyx Pharmaceuticals →
"Healey & AMG Center announces top line results in ALS platform trial with CMN-Au8," published by the Sean M. Healey & AMG Center for ALS →
"Verdiperstat Fails to Differentiate From Placebo in Critical HEALEY ALS Platform Trial," published by NeurologyLive →
"Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries," published by Amylyx Pharmaceuticals →
NEALS1245 →
NEALS1381 →
NEALS1244 →
NEALS5844 →
NCT04089696 →
NCT04332198 →
NCT04380649 →
NCT04391361 →
NCT04667013 →
NCT04695210 →
NCT04820478 →
NCT04840823 →
NCT04849065 →
NCT04894240 →
NCT04953494 →
NCT04997954 →
NCT04998305 →
NCT05033951 →
NCT05077696 →
NCT05105958 →
NCT05107349 →
NCT05136222 →
NCT05151211 →
NCT05189106 →
NCT05297487 →
NCT05299372 →
NCT05336760 →
NCT05349721 →
NCT05352958 →
NCT05358431 →
NCT05370079 →
NCT05395624 →
NCT05404867 →
NCT05407324 →
NCT05409508 →
NCT05423678 →
NCT05442775 →
NCT05470478 →
NCT05474235 →
NCT05498883 →
NCT05508074 →
NCT05542576 →
NCT05562960 →
NCT05568615 →
NCT05581771 →
ALS Himalaya trial: a global, double-blind, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR443820, a RIPK1 inhibitor, in adult participants with ALS →
Social Media at the 2024 Annual NEALS Meeting →
"FDA Extends Review Date for ALS Treatment Tofersen," published by NeurologyLive →
Annual NEALS Meeting →
Trials of the Future: Remote Monitoring →
NCT03204500 →
NCT03214146 →
NCT03241784 →
NCT03272802 →
NCT03285204 →
NCT03293394 →
NCT03296501 →
NCT03321487 →
NCT03324399 →
NCT03326622 →
NCT03330353 →
NCT03356288 →
NCT03359538 →
NCT03377309 →
NCT03377868 →
NCT03378375 →
NCT03382392 →
NCT03427086 →
NCT03444428 →
NCT03474263 →
NCT03481348 →
NCT03487263 →
NCT03487536 →
NCT03489200 →
NCT03508453 →
NCT03516994 →
NCT03519880 →
NCT03536962 →
NCT03545451 →
NCT03548311 →
NCT03560661 →
NCT03573466 →
NCT03604822 →
NCT03613571 →
NCT03618966 →
NCT03659422 →
NCT03664206 →
NCT03679975 →
NCT03683875 →
NCT03693781 →
NCT03694132 →
NCT03764384 →
NCT03787420 →
NCT03792490 →
NCT03797677 →
NCT03806634 →
NCT03806647 →
NCT03809845 →
NCT03811301 →
NCT03828123 →
NCT03876002 →
NCT03887338 →
NCT03892382 →
NCT03892863 →
NCT03900247 →
NCT03929068 →
NCT03975608 →
NCT03981536 →
NCT04055532 →
NCT04104373 →
NCT04140136 →
NCT04165850 →
NCT04172792 →
NCT04176224 →
NCT04226144 →
NCT04233099 →
NCT04240925 →
NCT04254913 →
NCT04305639 →
NCT04313166 →
NCT04430686 →
NCT04440644 →
NCT04446325 →
NCT04454840 →
NCT04455542 →
NCT04516096 →
NCT04651855 →
NCT04800926 →
NCT04821479 →
NCT04875949 →
NCT04889248 →
NCT04947436 →
NCT04948346 →
NCT04950231 →
NCT04952025 →
NCT04960540 →
NCT04961450 →
NCT05019014 →
NCT05106569 →
NCT05119387 →
NCT05292690 →
NCT05299658 →
NCT05314348 →
NCT05595850 →
NCT05619783 →
NCT05621213 →
Update on COURAGE-ALS: A Phase 3 Trial of Reldesemtiv, a Muscle Directed Drug →
Allison →
"Healey & AMG Center for ALS announces new drug regimen for testing DNL343 in HEALEY ALS Platform Trial," published by the Sean M. Healey & AMG Center for ALS →
ALSUntangled – Vitamins and Supplements in ALS →
"Mitsubishi Tanabe Pharma America Presents Interim Data from REFINE-ALS Biomarker Study at 21st Annual NEALS Meeting," published by Mitsubishi Tanabe Pharma America →
21st Annual NEALS Meeting Abstracts published in Muscle and Nerve →
David Buseck →
Chris Mulholland →
Diane Hoey →
Kaitlyn Pierce →
"BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study," published by BrainStorm Cell Therapeutics Inc. →
Phase 2 Trial of AP-101 in SOD1 and Sporadic ALS →
"Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS," published by Amylyx Pharmaceuticals →
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Rapa Therapeutics have announced the first participant enrolled in the Expanded Access to RAPA-501 Protocol (EAP →
Jody Dlouhy-Nelson →
Bryan Rosica →
Shaunak Dwivedi →
Ronald Faretra →
Debbie Lower →
Brian Heaney →
Alper Kaya →
Sarah Brendle →
Paula Trefiak →
Sandra Mikush →
Mark Buermann →
Robert Faulstich →
ERIN DITTOE →
"Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS," published by Biogen →
NEALS Webinar: An Update on Tofersen →
Heather Rombough →
The ALS Association Webinar: Tofersen and the FDA Approval Process →
Doug Butchart →
Why lumbar puncture and CSF biomarkers are important to ALS therapeutic development →
Sami Barmada, MD, PhD →
Rita Sattler, PhD, MSc →
Christina Fournier, MD, MSc →
Piera Pasinelli, PhD →
Senda Ajroud-Driss, MD →
NCT05632757 →
NCT05633459 →
NCT05695521 →
NCT05716074 →
NCT05724173 →
NCT05747937 →
NCT05753852 →
NCT05764434 →
NCT05768646 →
Palliative care for people with ALS →
Tofersen Update →
"FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS," published by Biogen →
The ALS Association Webinar: Implications of tofersen for everyone with ALS →
NCT05683860 →
NCT05725759 →
NCT05742828 →
NCT05744310 →
NCT05784727 →
NCT05795907 →
NCT05797701 →
NCT05797753 →
NCT05819931 →
NCT05829330 →
NCT05830214 →
NCT05837507 →
NCT05852405 →
NCT05852418 →
NCT05860244 →
National Institutes of Health (NIH) funds New Multi-Institutional ALS Clinical Research Consortium →
Understanding Statistical and Clinical Significance →
Christina Smith →
Webinar Utreloxastat (PTC857) and CARDINALS Study Overview →
National ALS Registry: Learn How You Can Join the Fight Against ALS →
The Science Behind ALS Treatments: Riluzole, Radicava, and Relyvrio →
The Benefits of Macronutrients in People Living with ALS: What Should We Eat? →
Bridging the Gap: The Crucial Role of Collaborative Pre-Clinical Research →
Constipation in People Living with ALS: Does Autonomic Dysfunction Play A Role? →
Dawn Baxter →
An Overview of The ALS Better Care Act →
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs →
Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related ALS →
Our Structure (dev) →
Test Pages →
Access for All in ALS (ALL ALS) Consortium →
Michael Madden →
Promising Alternative and Off-Label Treatments for ALS →
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy →
The Sean M. Healey & AMG Center for ALS and Prilenia Therapeutics Announce First Participant Enrolled in NIH-Sponsored ACT for ALS Expanded Access Protocol for Pridopidine →
ALS & PARTICIPATION IN CLINICAL RESEARCH →
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Rapa Therapeutics have announced the first participant enrolled in the Expanded Access to RAPA-501 Protocol (EAP) →
Les Turner ALS Foundation Releases Step-by-Step Patient Guide to Increase and Diversify Clinical Trial Participation →
Respiratory Care in ALS: Advances in Remote Monitoring in ALS →
Understanding the Role of Genetic Testing and Genetic Counseling for Individuals and Families Impacted by ALS →
Advances in Cough and Secretion Management in ALS →
Report Urges Immediate and Longer-Term Actions to Improve Quality of Health Care and Support Services for People with ALS, Speed Development of Therapies →
Himalaya Trial Update Webinar →
Umayangga →
Optimizing Non-Invasive Ventilation in ALS →
Healey & AMG Center for ALS Announces New Investigational Drug Monepantel from PharmAust Limited will begin design for inclusion in HEALEY ALS Platform Trial →
Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia →
Doug Hill →
Feeding Tubes for People Living with ALS: What You Need to Know Before Getting One →
First Participant Enrolled in NIH-Funded Access for All in ALS Consortium →
The Role of Biomarkers in ALS →
At the Crossroads: Advanced Respiratory Care in ALS →
CNM-Au8 Long-term Data Update: →
Jennifer Heinly →
Examining Psilocybin for Existential Distress in People with ALS →
The Role of AI in ALS →
Groundbreaking Directive Ensures ALS Patients on Medicare Advantage Gain Access to Qalsody →
Expanded Access Programs in ALS: What Have We Learned, Where Do We Go from Here? →
Exposomics and Epigenetic ALS insights: How exposures alter ALS risk and progression →
Sean M. Healey & AMG Center Announces Topline Results in HEALEY ALS Platform Trial with eIF2B Agonist DNL343 →
NEALS Year in Review and 2025 Initiatives Overview →
Bjorn E Oskarsson, MD →
Shafeeq S. Ladha, MD →
Practical Palliative Care Skills for the ALS/MND Clinicians →
ed mytych →
PEACe Committee →
Non-Pharmacological Treatments for ALS →
Stitching Strength: Things I Have Learned About Hope and How I am Trying to Weave These Into My Practice →
Brent T Harris, MD, PhD →
Kelly Gwathmey, MD →
30 Years of Progress: NEALS in Focus →
Empowering a Community Through the ALS Clinical Research Learning Institute® (CRLI) →
Amplifying the Voices of Those Living with ALS in Research →
Qalsody Conditionally Approved in Canada for ALS Linked to SOD1 Gene Mutations →
Feeding Tube Management and Consideration in People Living with ALS →